fluconazole has been researched along with Diseases of Pharynx in 51 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole." | 9.12 | A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. ( Gogate, J; Greaves, W; Isaacs, R; Nieto, L; Northland, R; Sanne, I; Skiest, DJ; Vazquez, JA, 2006) |
| "Fluconazole 50 mg daily for 14-28 days was effective in the treatment of patients with AIDS and AIDS-related complex with severe oropharyngeal and oesophageal candidiasis." | 9.06 | Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. ( Dunbar, EM; Ellis, ME; Leen, CL; Mandal, BK, 1990) |
| "Itraconazole and fluconazole are two relatively new anti-fungal agents which are being used successfully in the treatment of oropharyngeal candidiasis." | 8.78 | Itraconazole and fluconazole in oropharyngeal candidiasis. ( Arendorf, TM; van der Bijl, P, 1993) |
| " We studied the antifungal efficacy, the concentrations in saliva and tissue, and the safety of VER-002 at escalating dosages against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant Candida albicans in immunocompromised rabbits." | 7.71 | Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ, 2001) |
| "Oral candidiasis is a frequent opportunistic infection in AIDS patients." | 6.67 | [Fluconazole in oro-pharyngeal candidiasis in retroviral infection (experience in Dakar)]. ( Coll-Seck, AM; Diop, BM; Faye, MA; Ndiaye, I; Sow, PS, 1993) |
| "Fluconazole is a bis-triazole antifungal agent with a long serum half-life." | 6.67 | Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs. ( Hales, M; Kernoff, PB; Lee, CA; Lim, SG; O'Doherty, M; Winter, M, 1991) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 5.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| "This multicenter, randomized, evaluator-blinded study of subjects with HIV infection and oropharyngeal candidiasis compared efficacy of posaconazole with that of fluconazole." | 5.12 | A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. ( Gogate, J; Greaves, W; Isaacs, R; Nieto, L; Northland, R; Sanne, I; Skiest, DJ; Vazquez, JA, 2006) |
| "Fluconazole 50 mg daily for 14-28 days was effective in the treatment of patients with AIDS and AIDS-related complex with severe oropharyngeal and oesophageal candidiasis." | 5.06 | Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. ( Dunbar, EM; Ellis, ME; Leen, CL; Mandal, BK, 1990) |
| "In a randomised, double-blind study the efficacy and toxicity of oral fluconazole 50 mg daily and ketoconazole 200 mg daily were compared for the treatment of oropharyngeal candidiasis in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC)." | 5.06 | Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. ( Clumeck, N; De Wit, S; Goossens, H; Weerts, D, 1989) |
| "A systematic review of randomized clinical trials published between 1966 and April 2000 was undertaken to determine the strength of evidence for the effectiveness of antifungal drugs (nystatin, clotrimazole, amphotericin B, fluconazole, ketoconazole, and itraconazole) to prevent and treat oral candidiasis in human immunodeficiency virus-positive patients." | 4.81 | A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. ( Bonito, AJ; Patton, LL; Shugars, DA, 2001) |
| "Itraconazole and fluconazole are two relatively new anti-fungal agents which are being used successfully in the treatment of oropharyngeal candidiasis." | 4.78 | Itraconazole and fluconazole in oropharyngeal candidiasis. ( Arendorf, TM; van der Bijl, P, 1993) |
| " We studied the antifungal efficacy, the concentrations in saliva and tissue, and the safety of VER-002 at escalating dosages against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant Candida albicans in immunocompromised rabbits." | 3.71 | Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ, 2001) |
| "Random amplified polymorphic DNA analysis was used to detect genotype relatedness among clinical fluconazole-resistant and -sensitive strains of Candida albicans recovered from twenty HIV-infected patients having oropharyngeal candidiasis." | 3.71 | Variation in random amplified polymorphic DNA (RAPD) profiles specific to fluconazole-resistant and -sensitive strains of Candida albicans. ( Bhattacharya, E; Jain, P; Khan, ZK; Ranade, SA, 2001) |
| "Signs and symptoms of oropharyngeal candidiasis (OPC) were correlated with microbiology and clinical response to fluconazole in a cohort of patients with advanced human immunodeficiency virus (HIV) infection and recurrent OPC." | 3.70 | Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. ( Dib, OP; Fothergill, AW; Kirkpatrick, WR; McAtee, RK; Patterson, TF; Redding, SW; Revankar, SG; Rinaldi, MG, 1998) |
| "Oral candidiasis is a frequent opportunistic infection in AIDS patients." | 2.67 | [Fluconazole in oro-pharyngeal candidiasis in retroviral infection (experience in Dakar)]. ( Coll-Seck, AM; Diop, BM; Faye, MA; Ndiaye, I; Sow, PS, 1993) |
| "Fluconazole has proved to be effective in treating oropharyngeal and esophageal candidiasis in immunocompromised patients." | 2.67 | Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. ( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994) |
| "Fluconazole was given in a mean dosage of 3." | 2.67 | Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected]. ( Marchisio, P; Principi, N, 1994) |
| " Twenty-four subjects received oral fluconazole in a dosage of 3 mg/kg/day and 22 subjects received oral ketoconazole in a dosage of 7 mg/kg/day." | 2.67 | Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group. ( Hernández-Sampelayo, T, 1994) |
| "Fluconazole is a bis-triazole antifungal agent with a long serum half-life." | 2.67 | Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs. ( Hales, M; Kernoff, PB; Lee, CA; Lim, SG; O'Doherty, M; Winter, M, 1991) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 1.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| "Fluconazole treatment was ineffective for patients infected with resistant isolates; however, high doses of ketoconazole or itraconazole were successful for nine (81%) of them." | 1.30 | Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. ( Díaz-Guerra, TM; Dronda, F; Laguna, F; Martínez-Súarez, JV; Polo, R; Pulido, F; Rodríguez-Tudela, JL; Valencia, E, 1997) |
| "Treatment with fluconazole (100 mg/day) was successful in 86% of the cases." | 1.29 | Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. ( Baquero, F; Fortún, J; Giner, C; Guerrero, A; Navas, E; Pereira, E; Polanco, AM; Quereda, C; Sánchez-Sousa, A, 1996) |
| "Thirty adults (15 with ARC and 15 with AIDS) with a first episode of thrush candidiasis were given oral fluconazole (Triflucan 50 mg; one capsule daily) for at least three months." | 1.28 | [Treatment and secondary prophylaxis with fluconazole for oropharyngeal candidiasis in HIV-positive patients. A mycological analysis of failures]. ( André, D; Bastide, JM; Janbon, F; Mallié, M; Reynes, J, 1992) |
| "Fluconazole was well tolerated by all patients and there were no significant changes in haematological or hepatic parameters that could be attributed to the drug." | 1.27 | Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. ( Drouhet, E; Dupont, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.84) | 18.7374 |
| 1990's | 28 (54.90) | 18.2507 |
| 2000's | 16 (31.37) | 29.6817 |
| 2010's | 3 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Filette, J | 1 |
| Michiels, V | 1 |
| Salari, S | 1 |
| Khosravi, AR | 1 |
| Mousavi, SA | 1 |
| Nikbakht-Brojeni, GH | 1 |
| Enwuru, CA | 1 |
| Ogunledun, A | 1 |
| Idika, N | 1 |
| Enwuru, NV | 1 |
| Ogbonna, F | 1 |
| Aniedobe, M | 1 |
| Adeiga, A | 1 |
| Lopatin, AS | 1 |
| Ovchinnikov, AIu | 1 |
| Makarova, NU | 1 |
| Pokrowsky, VV | 1 |
| Kravchenko, AV | 1 |
| Serebrovskaya, LV | 1 |
| James, MJ | 1 |
| McNeil, MM | 1 |
| Lasker, BA | 1 |
| Warnock, DW | 1 |
| Reiss, E | 1 |
| Tapia, C | 1 |
| González, P | 1 |
| Pereira, A | 1 |
| Pérez, J | 1 |
| Noriega, LM | 1 |
| Palavecino, E | 1 |
| Redding, SW | 4 |
| Dahiya, MC | 1 |
| Kirkpatrick, WR | 8 |
| Coco, BJ | 2 |
| Patterson, TF | 8 |
| Fothergill, AW | 4 |
| Rinaldi, MG | 6 |
| Thomas, CR | 1 |
| Vazquez, JA | 1 |
| Skiest, DJ | 1 |
| Nieto, L | 1 |
| Northland, R | 1 |
| Sanne, I | 1 |
| Gogate, J | 1 |
| Greaves, W | 1 |
| Isaacs, R | 1 |
| Corvò, R | 1 |
| Amichetti, M | 1 |
| Ascarelli, A | 1 |
| Arcangeli, G | 1 |
| Buffoli, A | 1 |
| Cellini, N | 1 |
| Cionini, L | 1 |
| De Renzis, C | 1 |
| Emiliani, E | 1 |
| Franchini, P | 1 |
| Gabriele, P | 1 |
| Gobitti, C | 1 |
| Grillo Ruggieri, F | 1 |
| Bertoni, F | 1 |
| Magrini, SM | 1 |
| Marmiroli, L | 1 |
| Orsatti, M | 1 |
| Panizza, GM | 1 |
| Tordiglione, M | 1 |
| Ziccarelli, L | 1 |
| Gava, A | 1 |
| Zorat, PL | 1 |
| Ghelfi, R | 1 |
| Serra, GF | 1 |
| Vitale, V | 1 |
| Force, RW | 1 |
| Nahata, MC | 1 |
| Sow, PS | 1 |
| Diop, BM | 1 |
| Ndiaye, I | 1 |
| Faye, MA | 1 |
| Coll-Seck, AM | 1 |
| Bart-Delabesse, E | 1 |
| Boiron, P | 1 |
| Carlotti, A | 1 |
| Dupont, B | 2 |
| Corzo Delgado, JE | 1 |
| Lozano de León, F | 1 |
| Aretio Najarro, R | 1 |
| Martín Mazuelos, E | 1 |
| Akova, M | 2 |
| Akalin, HE | 1 |
| Uzun, O | 1 |
| Hayran, M | 2 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Aslan, S | 1 |
| Telatar, H | 1 |
| Marchisio, P | 1 |
| Principi, N | 1 |
| Hernández-Sampelayo, T | 1 |
| Troillet, N | 1 |
| Durussel, C | 1 |
| Bille, J | 1 |
| Glauser, MP | 1 |
| Chave, JP | 1 |
| van der Bijl, P | 1 |
| Arendorf, TM | 1 |
| Háber, J | 1 |
| Kolesková, E | 1 |
| Kostelková, A | 1 |
| Klener, P | 1 |
| Slavícek, A | 1 |
| Palecek, A | 1 |
| Másová, I | 1 |
| Barchiesi, F | 1 |
| Hollis, RJ | 1 |
| Del Poeta, M | 1 |
| McGough, DA | 1 |
| Scalise, G | 1 |
| Pfaller, MA | 1 |
| Quereda, C | 1 |
| Polanco, AM | 1 |
| Giner, C | 1 |
| Sánchez-Sousa, A | 1 |
| Pereira, E | 1 |
| Navas, E | 1 |
| Fortún, J | 1 |
| Guerrero, A | 1 |
| Baquero, F | 1 |
| Finlay, PM | 1 |
| Richardson, MD | 1 |
| Robertson, AG | 1 |
| Wildfeuer, A | 1 |
| Laufen, H | 1 |
| Yeates, RA | 1 |
| Zimmermann, T | 1 |
| Dronda, F | 2 |
| Alonso-Sanz, M | 1 |
| Laguna, F | 2 |
| Chaves, F | 1 |
| Martínez-Suárez, JV | 2 |
| Rodríguez-Tudela, JL | 2 |
| González-López, A | 1 |
| Valencia, E | 2 |
| Studena, V | 1 |
| Sycova, Z | 1 |
| Helpianska, L | 1 |
| Sorkovska, D | 1 |
| Pichna, P | 1 |
| Lacka, J | 1 |
| Hlavacova, E | 1 |
| Oravcova, E | 1 |
| Krcmery, V | 1 |
| Studena, M | 1 |
| Polo, R | 1 |
| Díaz-Guerra, TM | 1 |
| Pulido, F | 1 |
| Pons, V | 1 |
| Greenspan, D | 1 |
| Lozada-Nur, F | 1 |
| McPhail, L | 1 |
| Gallant, JE | 1 |
| Tunkel, A | 1 |
| Johnson, CC | 1 |
| McCarty, J | 1 |
| Panzer, H | 1 |
| Levenstein, M | 1 |
| Barranco, A | 1 |
| Green, S | 1 |
| Darouiche, RO | 1 |
| Arikan, S | 1 |
| Ozdemir, O | 1 |
| Erman, M | 1 |
| Gür, D | 1 |
| Unal, S | 1 |
| Revankar, SG | 1 |
| Dib, OP | 1 |
| McAtee, RK | 4 |
| Lopez-Ribot, JL | 5 |
| Lee, LN | 1 |
| White, TC | 1 |
| Sanglard, D | 1 |
| Masiá Canuto, MM | 1 |
| Gutiérrez Rodero, F | 1 |
| Ortiz de la Tabla Ducasse, V | 1 |
| Martín González, C | 1 |
| Escolano Hortelano, CM | 1 |
| Mora Rufete, A | 1 |
| Martín Hidalgo, A | 1 |
| Perea, S | 2 |
| La Valle, R | 1 |
| Walsh, TJ | 2 |
| Gonzalez, CE | 1 |
| Piscitelli, S | 1 |
| Bacher, JD | 1 |
| Peter, J | 1 |
| Torres, R | 1 |
| Shetti, D | 1 |
| Katsov, V | 1 |
| Kligys, K | 1 |
| Lyman, CA | 2 |
| Petraitis, V | 1 |
| Petraitiene, R | 1 |
| Groll, AH | 1 |
| Sein, T | 1 |
| Schaufele, RL | 1 |
| Francesconi, A | 1 |
| Bacher, J | 1 |
| Piscitelli, SC | 1 |
| Walmsley, S | 1 |
| King, S | 1 |
| McGeer, A | 1 |
| Ye, Y | 1 |
| Richardson, S | 1 |
| Bailey, CW | 1 |
| Samaranayake, YH | 1 |
| Samaranayake, LP | 2 |
| Tsang, PC | 1 |
| Wong, KH | 1 |
| Yeung, KW | 1 |
| Patton, LL | 1 |
| Bonito, AJ | 1 |
| Shugars, DA | 1 |
| Anil, S | 1 |
| Ellepola, AN | 1 |
| Jain, P | 1 |
| Khan, ZK | 1 |
| Bhattacharya, E | 1 |
| Ranade, SA | 1 |
| Martínez, M | 1 |
| Bachmann, SP | 1 |
| Ruesga, MT | 1 |
| Sadkowski, L | 1 |
| Eng, TY | 1 |
| Reynes, J | 1 |
| Mallié, M | 1 |
| André, D | 1 |
| Janbon, F | 1 |
| Bastide, JM | 1 |
| Lim, SG | 1 |
| Lee, CA | 1 |
| Hales, M | 1 |
| O'Doherty, M | 1 |
| Winter, M | 1 |
| Kernoff, PB | 1 |
| Leen, CL | 1 |
| Dunbar, EM | 1 |
| Ellis, ME | 1 |
| Mandal, BK | 1 |
| De Wit, S | 1 |
| Weerts, D | 1 |
| Goossens, H | 1 |
| Clumeck, N | 1 |
| Drouhet, E | 1 |
4 reviews available for fluconazole and Diseases of Pharynx
| Article | Year |
|---|---|
[Oropharyngeal candidiasis in the practical work of the otorhinolaryngologist].
Topics: Administration, Topical; Antifungal Agents; Candida albicans; Candidiasis; Diagnosis, Oral; Drug Res | 2010 |
Itraconazole and fluconazole in oropharyngeal candidiasis.
Topics: Antifungal Agents; Candidiasis; Candidiasis, Oral; Fluconazole; Humans; Itraconazole; Ketoconazole; | 1993 |
Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.
Topics: Antifungal Agents; Candidiasis, Oral; Drug Resistance, Microbial; Esophageal Diseases; Fluconazole; | 1998 |
A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Candidiasis, | 2001 |
13 trials available for fluconazole and Diseases of Pharynx
| Article | Year |
|---|---|
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis; Candidi | 2006 |
Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candidiasis, Oral; Double-Blind Metho | 2008 |
Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.
Topics: Administration, Oral; Adult; Candida albicans; Candidiasis; Chromatography, High Pressure Liquid; Cr | 1995 |
[Fluconazole in oro-pharyngeal candidiasis in retroviral infection (experience in Dakar)].
Topics: Adult; AIDS-Related Opportunistic Infections; Candidiasis; Candidiasis, Oral; Female; Fluconazole; H | 1993 |
Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.
Topics: Adult; Candida; Candidiasis, Oral; Esophageal Diseases; Female; Fluconazole; Humans; Male; Middle Ag | 1994 |
Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected].
Topics: Administration, Oral; Adolescent; AIDS-Related Opportunistic Infections; Body Weight; Candida; Candi | 1994 |
Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group.
Topics: Adolescent; Age Factors; AIDS-Related Opportunistic Infections; Candida; Candidiasis, Oral; Child; C | 1994 |
A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candidiasis, Oral; Colony Count, | 1996 |
Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial.
Topics: Adult; Aged; Antifungal Agents; Candidiasis, Oral; Fluconazole; Humans; Itraconazole; Middle Aged; N | 1995 |
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Fluconazole; Hum | 1997 |
Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.
Topics: Adolescent; Adult; Aged; Candidiasis; Candidiasis, Oral; Child; Double-Blind Method; Female; Flucona | 1991 |
Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Candidiasis, Oral; Clinical Trials | 1990 |
Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; AIDS-Related Complex; Candidi | 1989 |
34 other studies available for fluconazole and Diseases of Pharynx
| Article | Year |
|---|---|
Bleeding interaction between fluconazole and warfarin.
Topics: Aged; Anticoagulants; Antifungal Agents; Drug Interactions; Female; Fluconazole; Hematoma; Humans; P | 2018 |
Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; ATP Binding Cassette Transporter, S | 2016 |
Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidia | 2008 |
Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candi | 2003 |
[Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida albicans; Candidia | 2003 |
Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer.
Topics: Adult; Aged; Antifungal Agents; Candida glabrata; Candidiasis, Oral; Carcinoma, Squamous Cell; Chemo | 2004 |
Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole.
Topics: AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis; Drug Resistance, Microbial; Fl | 1993 |
[Progressive resistance to fluconazole in a patient with HIV infection and recurrent oropharyngeal candidiasis].
Topics: Adult; AIDS-Related Opportunistic Infections; Candidiasis; Candidiasis, Oral; Drug Resistance, Micro | 1994 |
Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis; Drug Resistance, Microb | 1993 |
[Treatment of oropharyngeal and esophageal mycoses in immunodeficient patients with fluconazole (Diflucan, Pfizer)].
Topics: Adult; Aged; Esophageal Diseases; Female; Fluconazole; Humans; Immunocompromised Host; Male; Middle | 1993 |
Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis, Oral; DNA, Fungal; Drug | 1995 |
Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconaz | 1996 |
[A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole].
Topics: Administration, Oral; Aged; Antifungal Agents; Candidiasis; Candidiasis, Oral; Cross-Over Studies; E | 1996 |
Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida; Candidiasis, Oral; Female; Fluconazole; Human | 1996 |
Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis, Oral | 1997 |
Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.
Topics: Adult; Antifungal Agents; Candidiasis, Oral; Female; Fluconazole; Humans; Male; Microbial Sensitivit | 1998 |
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Drug Resistance, Microbial; F | 1998 |
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candid | 1998 |
[Epidemiology of yeast colonization and oropharyngeal infection other than Candida albicans in patients with HIV infection].
Topics: Adult; Aged; Candida; Candidiasis; Female; Fluconazole; HIV Infections; Humans; Male; Microbial Sens | 1999 |
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candidiasis; Candidiasis, | 1999 |
Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Fungal; Antifungal Agents; Antigenic Variation; A | 1999 |
Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Animals; Candidiasis; Candidiasis, Oral; Child; Colony Count, Microbial; Disease Models, Animal; Dru | 2000 |
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candidiasis; Candidiasis, Oral; Drug Resi | 2001 |
Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Child; Dru | 2001 |
Candida dubliniensis in radiation-induced oropharyngeal candidiasis.
Topics: Adult; Antifungal Agents; Candida; Candida albicans; Candidiasis; Candidiasis, Oral; Carcinoma, Squa | 2001 |
Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Analysis of Variance; Antifungal Agent | 2001 |
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candida albicans; | 2001 |
Variation in random amplified polymorphic DNA (RAPD) profiles specific to fluconazole-resistant and -sensitive strains of Candida albicans.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; DNA, Fungal | 2001 |
Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug | 2002 |
Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Fluconazole; Head and Neck Neoplasms; Humans; Male; | 2002 |
[Treatment and secondary prophylaxis with fluconazole for oropharyngeal candidiasis in HIV-positive patients. A mycological analysis of failures].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Candida albicans; Candidiasis, Oral; Female; | 1992 |
Fluconazole found effective against candidiasis.
Topics: Candidiasis; Candidiasis, Oral; Fluconazole; Humans; Oropharynx; Pharyngeal Diseases | 1989 |
Fluconazole versus ketoconazole in oropharyngeal candidiasis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis, Oral; Female; Fluconazole; Humans; Ketoconazole; Ma | 1989 |
Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.
Topics: Adult; Aged; Candida albicans; Candidiasis; Candidiasis, Oral; Female; Fluconazole; HIV Seropositivi | 1988 |